GlassScriptPhysician profile
Asif Mohamed
NPI 1962484261
$30,610.45
in general payments reported to CMS, 2019-2025
40 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,808 · 2020: $6,741 · 2021: $11K · 2022: $970 · 2023: $1,144 · 2024: $875 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,226 · Education: $65.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,225.82 |
| Education | $65.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,196.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $9,724.21 | 2019-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $2,779.98 | 2019-2025 | |
| Lilly USA, LLC | $1,375.73 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amneal Pharmaceuticals LLC | $613.85 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $541.95 | 2019-2025 | Korlym |
| Abbott Laboratories | $493.98 | 2019-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $413.98 | 2019-2025 | Ozempic, Rybelsus |
| Mannkind Corporation | $385.90 | 2019-2021 | |
| Amgen INC. | $379.00 | 2019-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $224.10 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $149.66 | 2019-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $142.88 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $140.36 | 2022-2025 | Minimed 780g |
| Dexcom, INC. | $122.21 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.